CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways

BACKGROUND: Malignant gliomas are associated with a high mortality rate, and effective treatment options are limited. Thus, the development of novel targeted treatments to battle this deadly disease is imperative. METHODS: In this study, we investigated the in vitro effects of the novel reversible c...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Hematol Oncol
Glavni autori: Liu, Xuejiao, Chong, Yulong, Tu, Yiming, Liu, Ning, Yue, Chenglong, Qi, Zhenglei, Liu, Huize, Yao, Yao, Liu, Hongmei, Gao, Shangfeng, Niu, Mingshan, Yu, Rutong
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2016
Teme:
Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5059893/
https://ncbi.nlm.nih.gov/pubmed/27733172
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-016-0338-2
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items